Member Info for Soupdragon78

I'd disagree Jiving, the warrants were exercised before the EU Orphan Drug committee had their meeting, so the broker could not have possibly had any info on whether they had favoured it or not.

You can argue that we all were expecting this news anyway, so its hardly insider.

Any one of us could have bought 100m shares in the past week or two and then sold them into this news.

Broker buys in large volume last week and on the 16th April in anticipation of news, then sells into rise. Easy money for them.

Radika, my average is 0.51p and yes I'm very confident I will get it back plus a lot more.

You’re not important enough to see them FX.

Expect to see a DG interview on today’s news.

Glad I decided to be locked in

Perfect!

A matter of opinion.

Looks like it’s a cost saving exercise. Arch Law seem to promote that their services are flexible and consult on an as needed basis. So might just be a simple way of NFX reducing overheads

Thanks FFX,

That one was discussed in the February meeting which gave it a positive opinion, then ratified on April 16th.

https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-18-19-february-2025_en.pdf#page8

Thanks Dansey, it’s a near impossible task as an outsider to quite say whether NFX will be a success, so maybe first of all we should identify what we see as ‘success’.

Firstly I guess there is technical / pharmaceutical success. Does the product (NXP002) work and will it reach market?

As we all know, the majority of drugs in development don’t reach market and fail at clinical stage. So the key for Nuformix is more about whether they can realise some form of value on the potential.

So, will they successfully outlicence NXP002? This is think is a strong chance of success.

The company has indicated that there are multiple parties involved in talks and that they have undertaken further research at the request of them.

To me this shows that interested parties are looking at how they would position NXP002 within their portfolio, potentially looking at using it as complementary to their existing or late stage clinical development drugs. This then brings the possibility of entering clinical trials an advanced stage.

So, whilst I only have limited info to go on, the fact that there are likely 3 or 4 interested parties would make me say there’s a 50% or more chance of signing some form of outlicence.

Finally we then come to what price we judge being a success. For my sins, I have an average price of 0.51p now for 20m shares. So, anything that gives a mcap of £20m or above will see the sp above 1p and then I’ll see based on the info that comes to light that gets us to that position (if we do get to that position).

Maybe its me being thick again, but I generally don't expect commercially confidential information to be available on a public bulletin board.

I must be wrong... care to share your bank details since this is only a public bulletin board.

Ask the company.

Why do you expect anyone here to know?

Thanks FX, I'm just a bit thick thats all, I didn't understand that people were locked in until they decided they didn't want to be locked in.

Didn't realise being locked in meant you could let yourself out whenever you wanted.

How do they sell if they're locked in?

£10k worth of sells is not large volume.

Commercial confidentiality. End of conversation

They are confidential. No good reason for you to know who they are.

Nobody is locked in.

Or the company has agreed with them to release the funds